These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 8551900)
21. Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins. Devroey D; Velkeniers B; Duquet W; Betz W Acta Cardiol; 2003 Jun; 58(3):179-84. PubMed ID: 12846506 [TBL] [Abstract][Full Text] [Related]
22. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. Bruckert E; De Gennes JL; Malbecq W; Baigts F Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530 [TBL] [Abstract][Full Text] [Related]
25. [Overviews of fibrate]. Tada N Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141 [No Abstract] [Full Text] [Related]
26. Normocholesterolaemic dysslipidaemia: is there a role for fibrates? Hamilton-Craig I Med J Aust; 2001 Jun; 174(11):610; author reply 611. PubMed ID: 11453341 [No Abstract] [Full Text] [Related]
27. Effect of fibric acid derivatives on blood lipid and lipoprotein levels. Hunninghake DB; Peters JR Am J Med; 1987 Nov; 83(5B):44-9. PubMed ID: 3318453 [TBL] [Abstract][Full Text] [Related]
28. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Evans M; Anderson RA; Graham J; Ellis GR; Morris K; Davies S; Jackson SK; Lewis MJ; Frenneaux MP; Rees A Circulation; 2000 Apr; 101(15):1773-9. PubMed ID: 10769276 [TBL] [Abstract][Full Text] [Related]
29. [Antilipemic therapy in dyslipidemias in obese non-insulin-dependent diabetics (ONIDDM)]. Palel G; Coman A; Petrovanu R; Ungureanu D; Cojocaru M Rev Med Chir Soc Med Nat Iasi; 1997; 101(3-4):120-2. PubMed ID: 10756782 [TBL] [Abstract][Full Text] [Related]
30. A case for lipid-lowering? Durrington P Diabet Med; 2000 Sep; 17 Suppl 2():4-5. PubMed ID: 11048824 [No Abstract] [Full Text] [Related]
31. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Schonfeld G Atherosclerosis; 1994 Dec; 111(2):161-74. PubMed ID: 7718018 [TBL] [Abstract][Full Text] [Related]
32. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. Mikhailidis DP; Jagroon IA Metabolism; 2001 Nov; 50(11):1385-6. PubMed ID: 11715936 [No Abstract] [Full Text] [Related]
34. Implication of fibrate therapy for homocysteine. Goffin E; Jamar F; Desager JP; Devuyst O Lancet; 1999 Oct; 354(9185):1209. PubMed ID: 10513738 [No Abstract] [Full Text] [Related]
35. New developments in the treatment of low high-density lipoprotein cholesterol. Miller M Curr Atheroscler Rep; 1999 Jul; 1(1):24-30. PubMed ID: 11122688 [TBL] [Abstract][Full Text] [Related]
37. The hypolipidemic activity of novel benzofuran-2-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats: a comparison with bezafibrate. Shattat G; Al-Qirim T; Sweidan K; Shahwan M; El-Huneidi W; Al-Hiari Y J Enzyme Inhib Med Chem; 2010 Dec; 25(6):751-5. PubMed ID: 20590406 [TBL] [Abstract][Full Text] [Related]
38. [Treatment of familial combined hyperlipidemia]. Bruckert E Ann Endocrinol (Paris); 1997; 58(4):297-301. PubMed ID: 9436478 [No Abstract] [Full Text] [Related]
39. Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate. Beghin L; Capps N; Duhal N; Davies J; Staels B; Luc G Ann Clin Biochem; 1999 Jul; 36 ( Pt 4)():523-5. PubMed ID: 10456219 [No Abstract] [Full Text] [Related]
40. Effects of bezafibrate on low HDL-cholesterol in patients with ischaemic cerebrovascular disease: a pilot study. Noring L; Kjellin KG; Ledermann H J Int Med Res; 1981; 9(5):319-23. PubMed ID: 7297756 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]